Glycemic Variability Assessment in Newly Treated Exocrine Pancreatic Insufficiency With Type 1 Diabetes
Authors' conclusion
GV can aid in assessing response to new-onset medications, as was demonstrated in this article for n = 1 individual with type 1 diabetes (using an open-source AID) after commencing PERT for newly identified EPI. GV may be useful for evaluating the efficacy of new-onset medications for people with insulin-requiring diabetes.
Study context
- Population
- Individual with T1D using open-source automated insulin delivery (AID), newly identified EPI
- Participants
- 1 participants
- Comparison
- 1 month before vs 1 month after pancreatic enzyme replacement therapy (PERT) commencement
- Outcome
- Glycemic outcomes and glycemic variability (GV) after meals
- Follow-up
- 1 month before vs 1 month after PERT
Methodological detailsbefore-after comparison, self-tracked data, open-source AID, Diabetes data uploaded via Nightscout to Open Humans; macronutrient, PERT intake and EPI symptoms self-tracked
- Before-after comparison
- Self-tracked data
- Open-source AID
- Diabetes data uploaded via Nightscout to Open Humans; macronutrient, PERT intake and EPI symptoms self-tracked
Main finding
As reported in the abstract
- Time in range already above goal and improved further after PERT
- Glucose rate of change and excursions >180 mg/dL reduced
- Mean high blood glucose index reduced overall and more so at breakfast after PERT
Original publication
Glycemic Variability Assessment in Newly Treated Exocrine Pancreatic Insufficiency With Type 1 Diabetes. J Diabetes Sci Technol. Published 5 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →